ArticleEuropean thyroid journal2025
Dynamic risk stratification in patients with follicular thyroid carcinoma treated with lobectomy.
Article in European thyroid journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Previous studies showed that dynamic risk stratification (DRS) was also useful in differentiated thyroid carcinoma patients with lobectomy or total thyroidectomy without radioactive iodine. The aim of this study was to evaluate the DRS system in patients with follicular thyroid carcinoma (FTC) who underwent lobectomy alone. Methods: In total, 161 patients with FTC who were diagnosed between January 2005 and December 2014 and underwent lobectomy alone were included in this study. Results: Of the 161 patients with FTC, the DRS system classified 159 patients (99%) as having an excellent response, and 2 (1%) as having a structural-incomplete response. The 10-year disease-free survival (DFS) rates of patients with excellent response and structural-incomplete response were 93.5% and 0%, respectively (P < 0.001). Of the 54 patients with VI ≥ 2, the 10-year DFS rates of patients with excellent response (n = 53) and structural-incomplete response (n = 1) were 83.2% and 0%, respectively (P < 0.001). Of the 53 patients with excellent response, 10 patients experienced disease recurrence. Among Of these ten patients, the duration between initial thyroid surgery and recurrence was 2-5 years in one, 5-8 years in two, 8-10 years in four, and 10 years or more in three patients, respectively. Conclusion: Long-term follow-up may be needed in FTC patients treated with lobectomy alone even though they had an excellent response to initial thyroid surgery, especially in patients with a higher risk of recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.